Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics has reported that it intends to offer to sell, subject to market and other conditions, 2.67 million shares of its common stock in an underwritten public offering.
Subscribe to our email newsletter
In addition to the shares being offered by the company, 83,000 shares will be offered by a selling stockholder. The company will grant the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock at the public offering price.
The company intends to use the net proceeds from this offering to complete its second Phase III Fampridine-SR clinical trial in multiple sclerosis and to conduct other activities related to the filing of a new drug application and preparation for potential market launch of Fampridine-SR (if approved), for R&D and for general corporate purposes.